We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+19.3%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.75B
AUM Growth
+$73.2M
(+4.4%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-9.02%
Top 10 Holdings %
Top 10 Hldgs %
69.04%
Holding
38
New
9
Increased
6
Reduced
9
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$74.2M |
| 2 |
Ironwood Pharmaceuticals
IRWD
|
+$66.5M |
| 3 |
Viatris
VTRS
|
+$52M |
| 4 |
Coherus Oncology
CHRS
|
+$37.2M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$32.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$91.4M |
| 2 |
Ventas
VTR
|
+$87.1M |
| 3 |
HCA Healthcare
HCA
|
+$76.4M |
| 4 |
Biogen
BIIB
|
+$63.3M |
| 5 |
Tenet Healthcare
THC
|
+$50.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.98% |
| 2 | Technology | 10.19% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNTA
26
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $15M | 0.86% |
450,000
-1,550,000
| -78% | -$49.4M |
|
|
CBIO
27
Crescent Biopharma
CBIO
$610M
| $11.3M | 0.65% |
30,000
-5,000
| -14% | -$1.42M |
|
|
RDUS
28
DELISTED
Radius Health, Inc.
RDUS
| $5.11M | 0.29% |
+375,000
| New | +$5.16M |
|
29
Sutro Biopharma
STRO
$425M
| $4.66M | 0.27% |
60,000
| – | – |
|
|
30
AbbVie
ABBV
$429B
| – | – |
-1,200,000
| Closed | -$91.4M |
|
|
31
Biogen
BIIB
$30.1B
| – | – |
-200,000
| Closed | -$63.3M |
|
|
32
HCA Healthcare
HCA
$88.4B
| – | – |
-850,000
| Closed | -$76.4M |
|
33
Incyte
INCY
$23.6B
| – | – |
-360,457
| Closed | -$26.4M |
|
34
Pacific Biosciences
PACB
$367M
| – | – |
-2,500,000
| Closed | -$7.65M |
|
|
35
Tenet Healthcare
THC
$21B
| – | – |
-3,500,000
| Closed | -$50.4M |
|
|
36
Ventas
VTR
$47.2B
| – | – |
-3,250,000
| Closed | -$87.1M |
|
|
NUVA
37
DELISTED
NuVasive, Inc.
NUVA
| – | – |
-33,630
| Closed | -$1.7M |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Camber Capital Management held 38 positions worth $1.75B, up 4.4% from $1.67B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Camber Capital Management withdrew a net $158M in Q2 2020, closing 8 positions and reducing 9 holdings. Its most notable exit was AbbVie, an estimated $91.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Technology and Real Estate.
Against the trend, Camber Capital Management opened a new position in bluebird bio worth $77.8M.
- Camber Capital Management's largest Q2 2020 buy was bluebird bio: 98,430 shares worth $77.8M.
- Camber Capital Management added most to Viatris in Q2 2020, an estimated $52M increase.
- Camber Capital Management's biggest Q2 2020 reduction was Momenta Pharmaceuticals, Inc., cutting an estimated $49.4M.
- Camber Capital Management fully exited AbbVie in Q2 2020, selling an estimated $91.4M.
- Camber Capital Management's ten largest holdings make up 69% of its $1.75B portfolio in Q2 2020.
- Camber Capital Management opened 9 new positions and closed 8 in Q2 2020.
- Camber Capital Management's portfolio value rose 4.4% quarter-over-quarter to $1.75B.
Based on Camber Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.